108 related articles for article (PubMed ID: 9264073)
1. Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study.
Massi P; Patrini G; Rubino T; Fuzio D; Parolaro D
Pharmacol Biochem Behav; 1997 Sep; 58(1):73-8. PubMed ID: 9264073
[TBL] [Abstract][Full Text] [Related]
2. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
3. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids.
Lynn AB; Herkenham M
J Pharmacol Exp Ther; 1994 Mar; 268(3):1612-23. PubMed ID: 8138973
[TBL] [Abstract][Full Text] [Related]
4. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study.
Rubino T; Massi P; Patrini G; Venier I; Giagnoni G; Parolaro D
Neuroreport; 1994 Dec; 5(18):2493-6. PubMed ID: 7696588
[TBL] [Abstract][Full Text] [Related]
5. In vitro reinforcement of hippocampal bursting by the cannabinoid receptor agonist (-)-CP-55,940.
Xue BG; Belluzzi JD; Stein L
Brain Res; 1993 Oct; 626(1-2):272-7. PubMed ID: 8281436
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids and opioids share cAMP pathway in rat splenocytes.
Massi P; Vaccani A; Rubino T; Parolaro D
J Neuroimmunol; 2003 Dec; 145(1-2):46-54. PubMed ID: 14644030
[TBL] [Abstract][Full Text] [Related]
7. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound.
Patrini G; Sacerdote P; Fuzio D; Manfredi B; Parolaro D
J Neuroimmunol; 1997 Dec; 80(1-2):143-8. PubMed ID: 9413270
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
9. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation.
Kaminski NE; Abood ME; Kessler FK; Martin BR; Schatz AR
Mol Pharmacol; 1992 Nov; 42(5):736-42. PubMed ID: 1279376
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains.
Westlake TM; Howlett AC; Bonner TI; Matsuda LA; Herkenham M
Neuroscience; 1994 Dec; 63(3):637-52. PubMed ID: 7898667
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice.
Fan F; Tao Q; Abood M; Martin BR
Brain Res; 1996 Jan; 706(1):13-20. PubMed ID: 8720487
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction.
Chang MC; Berkery D; Schuel R; Laychock SG; Zimmerman AM; Zimmerman S; Schuel H
Mol Reprod Dev; 1993 Dec; 36(4):507-16. PubMed ID: 8305215
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
14. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
15. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
González S; Manzanares J; Berrendero F; Wenger T; Corchero J; Bisogno T; Romero J; Fuentes JA; Di Marzo V; Ramos JA; Fernández-Ruiz J
Neuroendocrinology; 1999 Aug; 70(2):137-45. PubMed ID: 10461028
[TBL] [Abstract][Full Text] [Related]
16. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
17. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.
Norwood CS; Cornish JL; Mallet PE; McGregor IS
Eur J Pharmacol; 2003 Mar; 465(1-2):105-14. PubMed ID: 12650839
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.
Rodríguez de Fonseca F; Gorriti MA; Fernández-Ruiz JJ; Palomo T; Ramos JA
Pharmacol Biochem Behav; 1994 Jan; 47(1):33-40. PubMed ID: 8115426
[TBL] [Abstract][Full Text] [Related]
19. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum.
Cadogan AK; Alexander SP; Boyd EA; Kendall DA
J Neurochem; 1997 Sep; 69(3):1131-7. PubMed ID: 9282935
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
